Browsing Tag
KEYNOTE-B96
3 posts
Ovarian cancer treatment options, survival rates, and the newest FDA approvals in 2026
Ovarian cancer affects 21,000 US women annually. This guide covers symptoms, staging, survival rates, BRCA risk, and the newest FDA-approved treatments through early 2026.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.
Merck’s KEYNOTE-B96 trial signals survival benefit in platinum-resistant ovarian cancer, but MRK stock dips
Merck's KEYNOTE-B96 trial shows survival benefit in ovarian cancer. See what it means for patients, pipeline, and MRK stock. Read full analysis now.